Human monoclonal antibodies as candidate therapeutics against emerging viruses and HIV-1.
Identifieur interne : 002650 ( Ncbi/Curation ); précédent : 002649; suivant : 002651Human monoclonal antibodies as candidate therapeutics against emerging viruses and HIV-1.
Auteurs : Zhongyu Zhu [États-Unis] ; Ponraj Prabakaran ; Weizao Chen ; Christopher C. Broder ; Rui Gong ; Dimiter S. DimitrovSource :
- Virologica Sinica [ 1995-820X ] ; 2013.
Descripteurs français
- KwdFr :
- Animaux, Anticorps monoclonaux (immunologie), Anticorps monoclonaux (usage thérapeutique), Humains, Maladies virales (), Maladies virales (immunologie), Maladies virales (traitement médicamenteux), VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (immunologie), VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (pathogénicité), Virus Hendra (immunologie), Virus Hendra (pathogénicité), Virus Nipah (immunologie), Virus Nipah (pathogénicité), Virus du SRAS (immunologie), Virus du SRAS (pathogénicité).
- MESH :
- immunologie : Anticorps monoclonaux, Maladies virales, VIH-1 (Virus de l'Immunodéficience Humaine de type 1), Virus Hendra, Virus Nipah, Virus du SRAS.
- pathogénicité : VIH-1 (Virus de l'Immunodéficience Humaine de type 1), Virus Hendra, Virus Nipah, Virus du SRAS.
- traitement médicamenteux : Maladies virales.
- usage thérapeutique : Anticorps monoclonaux.
- Animaux, Humains, Maladies virales.
English descriptors
- KwdEn :
- Animals, Antibodies, Monoclonal (immunology), Antibodies, Monoclonal (therapeutic use), HIV-1 (immunology), HIV-1 (pathogenicity), Hendra Virus (immunology), Hendra Virus (pathogenicity), Humans, Nipah Virus (immunology), Nipah Virus (pathogenicity), SARS Virus (immunology), SARS Virus (pathogenicity), Virus Diseases (drug therapy), Virus Diseases (immunology), Virus Diseases (prevention & control).
- MESH :
- chemical , immunology : Antibodies, Monoclonal.
- chemical , therapeutic use : Antibodies, Monoclonal.
- drug therapy : Virus Diseases.
- immunology : HIV-1, Hendra Virus, Nipah Virus, SARS Virus, Virus Diseases.
- pathogenicity : HIV-1, Hendra Virus, Nipah Virus, SARS Virus.
- prevention & control : Virus Diseases.
- Animals, Humans.
Abstract
More than 40 monoclonal antibodies (mAbs) have been approved for a number of disease indications with only one of these (Synagis) - for a viral disease, and not for therapy but for prevention. However, in the last decade novel potent mAbs have been discovered and characterized with potential as therapeutics against viruses of major importance for public health and biosecurity including Hendra virus (HeV), Nipah virus (NiV), severe acute respiratory syndrome coronavirus (SARS-CoV), Ebola virus (EBOV), West Nile virus (WNV), influenza virus (IFV) and human immunodeficiency virus type 1 (HIV-1). Here, we review such mAbs with an emphasis on antibodies of human origin, and highlight recent results as well as technologies and mechanisms related to their potential as therapeutics.
DOI: 10.1007/s12250-013-3313-x
PubMed: 23575729
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001222
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :001222
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001166
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :002650
Links to Exploration step
pubmed:23575729Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Human monoclonal antibodies as candidate therapeutics against emerging viruses and HIV-1.</title><author><name sortKey="Zhu, Zhongyu" sort="Zhu, Zhongyu" uniqKey="Zhu Z" first="Zhongyu" last="Zhu">Zhongyu Zhu</name><affiliation wicri:level="2"><nlm:affiliation>Protein Interactions Group, National Cancer Institute, National Institutes of Health, Frederick, MD 21702, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Protein Interactions Group, National Cancer Institute, National Institutes of Health, Frederick, MD 21702</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Prabakaran, Ponraj" sort="Prabakaran, Ponraj" uniqKey="Prabakaran P" first="Ponraj" last="Prabakaran">Ponraj Prabakaran</name></author><author><name sortKey="Chen, Weizao" sort="Chen, Weizao" uniqKey="Chen W" first="Weizao" last="Chen">Weizao Chen</name></author><author><name sortKey="Broder, Christopher C" sort="Broder, Christopher C" uniqKey="Broder C" first="Christopher C" last="Broder">Christopher C. Broder</name></author><author><name sortKey="Gong, Rui" sort="Gong, Rui" uniqKey="Gong R" first="Rui" last="Gong">Rui Gong</name></author><author><name sortKey="Dimitrov, Dimiter S" sort="Dimitrov, Dimiter S" uniqKey="Dimitrov D" first="Dimiter S" last="Dimitrov">Dimiter S. Dimitrov</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2013">2013</date><idno type="RBID">pubmed:23575729</idno><idno type="pmid">23575729</idno><idno type="doi">10.1007/s12250-013-3313-x</idno><idno type="wicri:Area/PubMed/Corpus">001222</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001222</idno><idno type="wicri:Area/PubMed/Curation">001222</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001222</idno><idno type="wicri:Area/PubMed/Checkpoint">001166</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001166</idno><idno type="wicri:Area/Ncbi/Merge">002650</idno><idno type="wicri:Area/Ncbi/Curation">002650</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Human monoclonal antibodies as candidate therapeutics against emerging viruses and HIV-1.</title><author><name sortKey="Zhu, Zhongyu" sort="Zhu, Zhongyu" uniqKey="Zhu Z" first="Zhongyu" last="Zhu">Zhongyu Zhu</name><affiliation wicri:level="2"><nlm:affiliation>Protein Interactions Group, National Cancer Institute, National Institutes of Health, Frederick, MD 21702, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Protein Interactions Group, National Cancer Institute, National Institutes of Health, Frederick, MD 21702</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Prabakaran, Ponraj" sort="Prabakaran, Ponraj" uniqKey="Prabakaran P" first="Ponraj" last="Prabakaran">Ponraj Prabakaran</name></author><author><name sortKey="Chen, Weizao" sort="Chen, Weizao" uniqKey="Chen W" first="Weizao" last="Chen">Weizao Chen</name></author><author><name sortKey="Broder, Christopher C" sort="Broder, Christopher C" uniqKey="Broder C" first="Christopher C" last="Broder">Christopher C. Broder</name></author><author><name sortKey="Gong, Rui" sort="Gong, Rui" uniqKey="Gong R" first="Rui" last="Gong">Rui Gong</name></author><author><name sortKey="Dimitrov, Dimiter S" sort="Dimitrov, Dimiter S" uniqKey="Dimitrov D" first="Dimiter S" last="Dimitrov">Dimiter S. Dimitrov</name></author></analytic><series><title level="j">Virologica Sinica</title><idno type="eISSN">1995-820X</idno><imprint><date when="2013" type="published">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antibodies, Monoclonal (immunology)</term><term>Antibodies, Monoclonal (therapeutic use)</term><term>HIV-1 (immunology)</term><term>HIV-1 (pathogenicity)</term><term>Hendra Virus (immunology)</term><term>Hendra Virus (pathogenicity)</term><term>Humans</term><term>Nipah Virus (immunology)</term><term>Nipah Virus (pathogenicity)</term><term>SARS Virus (immunology)</term><term>SARS Virus (pathogenicity)</term><term>Virus Diseases (drug therapy)</term><term>Virus Diseases (immunology)</term><term>Virus Diseases (prevention & control)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Anticorps monoclonaux (immunologie)</term><term>Anticorps monoclonaux (usage thérapeutique)</term><term>Humains</term><term>Maladies virales ()</term><term>Maladies virales (immunologie)</term><term>Maladies virales (traitement médicamenteux)</term><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (immunologie)</term><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (pathogénicité)</term><term>Virus Hendra (immunologie)</term><term>Virus Hendra (pathogénicité)</term><term>Virus Nipah (immunologie)</term><term>Virus Nipah (pathogénicité)</term><term>Virus du SRAS (immunologie)</term><term>Virus du SRAS (pathogénicité)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Monoclonal</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antibodies, Monoclonal</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Virus Diseases</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Anticorps monoclonaux</term><term>Maladies virales</term><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1)</term><term>Virus Hendra</term><term>Virus Nipah</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>HIV-1</term><term>Hendra Virus</term><term>Nipah Virus</term><term>SARS Virus</term><term>Virus Diseases</term></keywords><keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en"><term>HIV-1</term><term>Hendra Virus</term><term>Nipah Virus</term><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="pathogénicité" xml:lang="fr"><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1)</term><term>Virus Hendra</term><term>Virus Nipah</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Virus Diseases</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Maladies virales</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Anticorps monoclonaux</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Humans</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Humains</term><term>Maladies virales</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">More than 40 monoclonal antibodies (mAbs) have been approved for a number of disease indications with only one of these (Synagis) - for a viral disease, and not for therapy but for prevention. However, in the last decade novel potent mAbs have been discovered and characterized with potential as therapeutics against viruses of major importance for public health and biosecurity including Hendra virus (HeV), Nipah virus (NiV), severe acute respiratory syndrome coronavirus (SARS-CoV), Ebola virus (EBOV), West Nile virus (WNV), influenza virus (IFV) and human immunodeficiency virus type 1 (HIV-1). Here, we review such mAbs with an emphasis on antibodies of human origin, and highlight recent results as well as technologies and mechanisms related to their potential as therapeutics.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002650 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 002650 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Ncbi
|étape= Curation
|type= RBID
|clé= pubmed:23575729
|texte= Human monoclonal antibodies as candidate therapeutics against emerging viruses and HIV-1.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i -Sk "pubmed:23575729" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |